Aktie A2N38H ARIDIS PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Aridis Pharmaceuticals, Inc.

Aktien

A2N38H

US0403341045

ARDS

Verzögert OTC Markets
Andere Börsenplätze
 19:08:39 14.05.2024 		% 5 Tage % 1. Jan.
0,06 USD -4,00 % Intraday Chart für Aridis Pharmaceuticals, Inc. -9,09 % -14,41 %
2023 Aridis Pharmaceuticals, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI
2023 Aridis Pharmaceuticals, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer
Aridis Pharmaceuticals Announces $2 Million Offering
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index
Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K
Sector Update: Health Care Stocks Steady Premarket Tuesday
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2N38H Aktie
  4. Nachrichten Aridis Pharmaceuticals, Inc.
  5. Andere Sprachen